

Leroy A. Richardson,
*Chief, Information Collection Review Office,
 Office of Scientific Integrity, Office of the
 Associate Director for Science, Office of the
 Director, Centers for Disease Control and
 Prevention.*

[FR Doc. 2016-19460 Filed 8-15-16; 8:45 am]

BILLING CODE 4163-18-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

[Docket No. CDC-2016-0083; 60Day-16-
 16AWM]

Proposed Data Collection Submitted for Public Comment and Recommendations

AGENCY: Centers for Disease Control and
 Prevention, Department of Health and
 Human Services.

ACTION: Notice with comment period.

SUMMARY: Centers for Disease Control
 and Prevention as part of its continuing
 efforts to reduce public burden and
 maximize the utility of government
 information, invites the general public
 and other Federal agencies to take this
 opportunity to comment on this
 proposed information collections, as
 required by the Paperwork Reduction
 Act of 1995. This notice invites
 comment on the Executive and
 Scientific Resources Office Access
 Management System (EAMTS). EAMTS
 is designed to house all Guest
 Researcher & ORISE program packets,
 Appointment Mechanism Determination
 Forms, and Title 42 Fellowship
 Immigration information in one central
 location on the Human Resources Office
 SharePoint Server.

DATES: Written comments must be
 received on or before October 17, 2016.

ADDRESSES: You may submit comments,
 identified by Docket No. CDC-2016-
 0083 by any of the following methods:
 Federal eRulemaking Portal:
Regulations.gov. Follow the instructions
 for submitting comments.

Mail: Jeffrey M. Zirger, Acting
 Information Collection Review Office,
 Centers for Disease Control and
 Prevention, 1600 Clifton Road NE., MS-
 D74, Atlanta, Georgia 30329.

Instructions: All submissions received
 must include the agency name and
 Docket Number. All relevant comments
 received will be posted without change
 to *Regulations.gov*, including any
 personal information provided. For
 access to the docket to read background
 documents or comments received, go to
Regulations.gov.

Note: All public comment should be
 submitted through the Federal eRulemaking
 portal (*Regulations.gov*) or by U.S. mail to the
 address listed above.

FOR FURTHER INFORMATION CONTACT: To
 request more information on the
 proposed project or to obtain a copy of
 the information collection plan and
 instruments, contact the Information
 Collection Review Office, Centers for
 Disease Control and Prevention, 1600
 Clifton Road NE., MS-D74, Atlanta,
 Georgia 30329; phone: 404-639-7570;
 Email: *omb@cdc.gov*.

SUPPLEMENTARY INFORMATION: Under the
 Paperwork Reduction Act of 1995 (PRA)
 (44 U.S.C. 3501-3520), Federal agencies
 must obtain approval from the Office of
 Management and Budget (OMB) for each
 collection of information they conduct
 or sponsor. In addition, the PRA also
 requires Federal agencies to provide a
 60-day notice in the **Federal Register**
 concerning each proposed collection of
 information, including each new
 proposed collection, each proposed
 extension of existing collection of
 information, and each reinstatement of
 previously approved information
 collection before submitting the
 collection to OMB for approval. To
 comply with this requirement, we are
 publishing this notice of a proposed
 data collection as described below.

Comments are invited on: (a) Whether
 the proposed collection of information
 is necessary for the proper performance
 of the functions of the agency, including
 whether the information shall have
 practical utility; (b) the accuracy of the
 agency's estimate of the burden of the
 proposed collection of information; (c)
 ways to enhance the quality, utility, and
 clarity of the information to be
 collected; (d) ways to minimize the
 burden of the collection of information
 on respondents, including through the
 use of automated collection techniques
 or other forms of information
 technology; and (e) estimates of capital
 or start-up costs and costs of operation,
 maintenance, and purchase of services
 to provide information. Burden means
 the total time, effort, or financial
 resources expended by persons to
 generate, maintain, retain, disclose or
 provide information to or for a Federal
 agency. This includes the time needed
 to review instructions; to develop,
 acquire, install and utilize technology
 and systems for the purpose of
 collecting, validating and verifying
 information, processing and
 maintaining information, and disclosing
 and providing information; to train
 personnel and to be able to respond to
 a collection of information, to search
 data sources, to complete and review

the collection of information; and to
 transmit or otherwise disclose the
 information.

Proposed Project

Data Management for Executive and
 Scientific Resources Access
 Management Tracking System—New—
 Executive and Scientific Resource Office
 (ESRO), Centers for Disease Control and
 Prevention (CDC).

Background and Brief Description

ESRO seeks to submit and
 information collection request for
 approval of information collections
 through its ESRO Access Management
 Tracking System (EAMTS). This system
 will automate current manual processes
 for programs managed by ESRO. This
 new process will provide users a single,
 integrated location to allow for
 collaboration, faster processing between
 the programs and ESRO and a better
 onboarding experience for potential
 fellows.

EAMTS will support users by
 providing a single, integrated location
 for enterprise content management,
 manage documents and records by using
 workflows an information rights
 management. This business process will
 allow ESRO to design forms that are
 accessible in SharePoint through a Web
 Browser. Team members will be able to
 access critical business information,
 analyze and view data, and publish
 reports to make more informed
 decisions.

EAMTS will allow CIO's to submit
 digital packets including Guest
 Researcher, ORISE, Title 42 Fellowship
 Visa request (portion of CDC 0.1475)
 and Appointment Mechanism
 Determination Request Form (CDC
 0.4601). CIO's can upload supplemental
 documentation as an attachment to each
 application, electronically track and
 monitor status of application, digitally
 sign forms and requests, receive case
 determinations quickly and accurately,
 and track the Visa status of Title 42
 Fellowship requests that require Visa
 assistance from the Human Resources
 Office.

EAMTS is developed in SharePoint
 for CDC's Centers/Institutes/Offices
 (CIO) to submit required information for
 all of Executive and Scientific Resource
 Office's managed programs and for these
 CIO's to effectively and efficiently
 digitally review this information. Data is
 managed and maintained by appropriate
 CIO Staff with ground and form level
 permission.

Permissions to EAMTS are required to
 access the lists, forms, and document
 library. This includes entering data,

clearing/approving forms, processing forms, and acknowledging data entered.

The total estimated annualized burden hours for all respondents are 1,280. There are no costs to respondents

other than their time. CDC will seek a three-year approval from OMB.

ESTIMATED ANNUALIZED BURDEN HOURS

Type of respondents	Form name	Number of respondents	Number of responses per CIO	Average burden per response (in hours)	Total burden (in hours)
Initiator/C//O	CDC 0.4601	64	5	1	320
Initiator/C//O	CDC 0.410A	64	5	1	320
Initiator/C//O	CDC 0.410B	64	5	1	320
Initiator/C//O	Section C of the CDC 0.1475	64	5	1	320
Totals	1,280

Leroy A. Richardson,
Chief, Information Collection Review Office, Office of Scientific Integrity, Office of the Associate Director for Science, Office of the Director, Centers for Disease Control and Prevention.

[FR Doc. 2016-19461 Filed 8-15-16; 8:45 am]

BILLING CODE 4163-18-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Institute of Allergy and Infectious Diseases; Notice of Closed Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: National Institute of Allergy and Infectious Diseases Special Emphasis Panel; NIAID Clinical Trial Implementation Cooperative Agreement (U01).

Date: September 22, 2016.

Time: 10:00 a.m. to 12:00 p.m.

Agenda: To review and evaluate grant applications.

Place: National Institutes of Health, Room 3F100, 5601 Fishers Lane, Rockville, MD 20892 (Telephone Conference Call).

Contact Person: Lynn Rust, Ph.D., Scientific Review Officer, Scientific Review Program, Division of Extramural Activities, Room 3G42A, National Institutes of Health/ NIAID, 5601 Fishers Lane, MSC 9823,

Bethesda, MD 20892-9823, (240) 669-5069, lrust@niaid.nih.gov.

(Catalogue of Federal Domestic Assistance Program Nos. 93.855, Allergy, Immunology, and Transplantation Research; 93.856, Microbiology and Infectious Diseases Research, National Institutes of Health, HHS)

Dated: August 10, 2016.

Natasha M. Copeland,
Program Analyst, Office of Federal Advisory Committee Policy.

[FR Doc. 2016-19417 Filed 8-15-16; 8:45 am]

BILLING CODE 4140-01-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Prospective Grant of Start-Up Exclusive Evaluation Option License Agreement: Small Molecule Therapeutic Compounds Encompassed Within the Licensed Patent Rights for the Treatment of Thioesterase Deficiency Disorder

AGENCY: National Institutes of Health, HHS.

ACTION: Notice.

SUMMARY: This notice, in accordance with 35 U.S.C. 209 and 37 CFR part 404, that the National Institutes of Health, Department of Health and Human Services, is contemplating the grant of a Start-Up Exclusive Evaluation Option License Agreement to practice the inventions embodied in the following Patent Applications to Circumvent Pharmaceuticals Inc. (“Circumvent”) located in Pasadena, California, USA:

Intellectual Property

United States Provisional Patent Application No. 61/473,692, filed April 8, 2011, titled “Small molecule therapeutic compounds targeting thioesterase deficiency disorders and methods of using the same” [HHS

Reference No. E-157-2011/0-US-01], status: Expired;

International Patent Application No. PCT/US2012/32772 filed April 9, 2012 titled “Small molecule therapeutic compounds targeting thioesterase deficiency disorders and methods of using the same” [HHS Reference No. E-157-2011/0-PCT-02], status: Converted;

European Patent Application No. 12716889.6, filed November 7, 2013, titled “Small molecule therapeutic compounds targeting thioesterase deficiency disorders and methods of using the same” [HHS Reference No. E-157-2011/0-EP-03], status: Pending; and

United States Patent Application No. 14/110,393, filed October 7, 2013, titled “Small molecule therapeutic compounds targeting thioesterase deficiency disorders and methods of using the same” [HHS Reference No. E-157-2011/0-US-04], status: Pending.

The patent rights in these inventions have been assigned and/or exclusively licensed to the government of the United States of America.

The territory of the prospective Start-Up Exclusive Evaluation Option License Agreement may be worldwide and the field of use may be limited to: “Small molecule therapeutic compounds encompassed within the Licensed Patent Rights for the treatment of thioesterase deficiency disorders”

Upon the expiration or termination of the Start-up Exclusive Evaluation Option License Agreement, Circumvent will have the exclusive right to execute a Start-Up Exclusive Patent License Agreement which will supersede and replace the Start-up Exclusive Evaluation Option License Agreement, with no greater field of use and territory than granted in the Start-up Exclusive Evaluation Option License Agreement.

DATES: Only written comments and/or applications for a license which are received by the NIH Office of